Linzagolix
This oral medication works by blocking GnRH receptors in the pituitary gland, reducing the production of sex hormones that fuel endometriosis and uterine fibroids, thereby reducing pain and bleeding. Unlike injected GnRH treatments, it is taken as a daily pill.
Molekularmasse
508,4000 g/mol
LogP
3,40
TPSA
143,00 Ų
Lipinski-Regel der Fünf
Nicht bestanden
Therapeutische Bereiche
Wirkmechanismus
Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.
2D-Struktur
Cite this structure
Embed this structure
SMILES
COc1cc(F)c(-n2c(=O)[nH]c3csc(C(=O)O)c3c2=O)cc1OCc1c(OC)ccc(F)c1F
InChI
InChI=1S/C22H15F3N2O7S/c1-32-14-4-3-10(23)18(25)9(14)7-34-16-6-13(11(24)5-15(16)33-2)27-20(28)17-12(26-22(27)31)8-35-19(17)21(29)30/h3-6,8H,7H2,1-2H3,(H,26,31)(H,29,30)
Molecular Formula
C22H15F3N2O7S
HBD / HBA
2 / 11
Rotierbare Bindungen
7
Schwere Atome
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
This oral medication works by blocking GnRH receptors in the pituitary gland, reducing the production of sex hormones that fuel endometriosis and uterine fibroids, thereby reducing pain and bleeding. Unlike injected GnRH treatments, it is taken as a daily pill.
Modulates gonadotropin-releasing hormone (GnRH) signaling, ultimately suppressing luteinizing hormone and follicle-stimulating hormone secretion and reducing gonadal steroid hormone production.
Yes, Linzagolix is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3668014. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 16656889. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="linzagolix"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/linzagolix/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/linzagolix/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/linzagolix/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="linzagolix"></drugfyi-drug>